PT-141 (Bremelanotide) Side Effects

Reported PT-141 (Bremelanotide) side effects

Very Common (>10% of users) Nausea — By far the most common adverse effect, affecting approximately 40% of users in the RECONNECT trials. Usually mild-to-moderate, begins within 30-60 minutes of injection, resolves within 2-4 hours. Can be mitigated with slower dose escalation (start at 0.5 mg), taking PT-141 with a light snack or anti-emetic like ondansetron, and injecting at bedtime if anticipating activity the following morning. Flushing — Pink/red flush of the face and chest, typically appearing 15-30 minutes post-injection and fading over 1-2 hours. Caused by MSH-mediated vasodilation. Injection site reactions — Mild erythema, transient itching at the subcutaneous injection site. Site rotation reduces incidence. Headache — Mild to moderate, usually responsive to hydration and OTC analgesics. Common (1-10%) Vomiting — In a minority of users whose nausea is severe enough to progress. Immediate-onset vomiting within 30 minutes of injection is most common in first-time users at full 1.75-2 mg doses. Transient blood pressure elevation — +6 to +8 mmHg systolic increase in the first 4-8 hours post-injection, peaking around hours 2-4. Usually resolves by 12 hours. Significant enough that the FDA label contraindicates use in patients with uncontrolled hypertension or established cardiovascular disease. Paresthesia / tingling — Particularly in the scalp, face, or extremities. Typically transient and benign. Dysgeusia — Metallic or unusual taste lasting minutes post-injection. Nasal congestion — Minor, self-limiting. Dose-Dependent with Repeated Use Hyperpigmentation (melanocyte stimulation) — Dose-dependent darkening of skin, most commonly appearing as: New or enlarging freckles and nevi Diffuse facial pigmentation Darker areas on the gums Darker areolae This effect is caused by residual MC1R agonist activity and scales with cumulative dose. Users with high Fitzpatrick skin type (I-II) generally show the effect earlier; darker skin types may show less visible change. Existing nevus darkening — Rare reports of pre-existing moles darkening or changing. Any new or changing pigmented lesion warrants dermatology evaluation. Less Common / Rare Spontaneous erections in men (the original Melanotan-II observation; technically a pharmacodynamic effect but potentially unwanted in some contexts) Severe or persistent nausea requiring dose reduction Hypersensitivity reactions — rare; local swelling or systemic reaction Emesis-associated dehydration in users who experience severe nausea and do not maintain hydration Serious but Rare Clinically significant blood pressure elevation in users with unrecognized hypertension — this is the primary safety concern driving the FDA contraindication Syncope — rare, usually vasovagal, more common in first-time users Contraindicated Situations Uncontrolled hypertension (SBP >160 or DBP >100) Established cardiovascular disease (prior MI, stroke, heart failure, significant CAD) Concurrent use with PDE5 inhibitors — not absolutely contraindicated in FDA labeling but cumulative blood pressure effects warrant caution and typically dose separation of 12+ hours Pregnancy (no established safety data)

When to continue, reduce, or stop PT-141 (Bremelanotide)

PT-141 (Bremelanotide) contraindications

PT-141 / bremelanotide is contraindicated or requires extreme caution in: Uncontrolled hypertension (SBP >160 or DBP >100) — the transient blood pressure elevation PT-141 produces is additive to an already elevated baseline; may produce clinically significant hypertension Established cardiovascular disease — prior MI, stroke, heart failure, significant coronary artery disease, or ongoing unstable angina Significant peripheral vascular disease Pregnancy — no established safety data; MC4R activation during pregnancy has theoretical effects on fetal development Breastfeeding — no established safety data Known hypersensitivity to bremelanotide or any excipient Relative cautions (use with supervision and monitoring): Controlled but documented hypertension — verify BP is consistently <140/90 before each dose, monitor for 4 hours post-dose during initial uses History of syncope or vasovagal reactions Concurrent use of PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — cumulative blood pressure effects; separate dosing by 2+ hours when combining Concurrent use of sympathomimetics (decongestants, high-dose caffeine, pre-workouts containing yohimbine or DMHA) Personal or strong family history of melanoma — theoretical concern about MC1R activation and pigmented lesion stimulation Fitzpatrick skin type I-II users planning frequent use — pigmentation changes are more visible and develop faster Active gastrointestinal disease — the nausea effect may be poorly tolerated Users on MAO inhibitors — theoretical pharmacodynamic concerns; avoid combination Active psychiatric instability — sexual function is complex psychologically; medicalizing an arousal issue that is primarily psychological is not appropriate Drug-drug interactions: Cytochrome P450 substrate interactions — PT-141 is eliminated via proteolytic degradation rather than hepatic CYP metabolism, so direct P450 interactions are minimal Antihypertensive medications — Users on antihypertensives should monitor for breakthrough elevations in the post-injection window; the PT-141 blood pressure effect may overcome modest antihypertensive coverage Opioids — Increased nausea when combined; additive CNS depression in higher doses Discontinuation triggers: Any new or changing pigmented skin lesion Persistent blood pressure elevation beyond the 12-hour post-dose window Chest pain, shortness of breath, or other cardiovascular symptoms following dosing Severe intractable nausea not controllable with standard anti-emetic measures Any signs of hypersensitivity or systemic allergic reaction

Why vendor quality drives PT-141 (Bremelanotide) side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

PT-141 (Bremelanotide) side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .